Hutchison China MediTech: Recall authorization for the tumor innovation drug Dovek® introduced for only one year

LightningPacketLoss · 2026-03-10T09:10:40+00:00

Hutchison China MediTech announces that due to GlaxoSmithKline's global strategic decision, it will withdraw and recall the oncology drug Dovepra® (Tazelesimab) in Mainland China, Hong Kong, and Macau, and will also cease related clinical trials. Patients are advised to consult their doctors to discuss treatment options.

LightningPacketLoss

2026-03-10 09:10:40

Abstract generation in progress

Recently, Hutchison China MediTech announced that, due to the strategic decisions of its licensing partner Ipsen, its oncology drug Tazemetostat (达唯珂®) marketed in Mainland China, Hong Kong, and Macau has officially begun the withdrawal and recall process, and all related clinical trials have been halted.

Tazemetostat is an oncology medication licensed by Ipsen’s subsidiary Epizyme, Inc. (“Epizyme”). Epizyme holds the marketing authorization for Tazemetostat in Mainland China, with Hutchison China MediTech (Shanghai) Co., Ltd. designated as its domestic agent/authorized representative.

The announcement states that Ipsen has informed Hutchison China MediTech of its voluntary withdrawal of Tazemetostat in the United States. Accordingly, measures have been taken to initiate withdrawal and recall procedures in China. Hutchison China MediTech (Shanghai) Co., Ltd. has promptly started the withdrawal and recall of the product in Mainland China, Hong Kong, and Macau, and all ongoing clinical trials involving Tazemetostat have been halted. Current patients should immediately consult their healthcare providers to discuss treatment options.

(Hutchison China MediTech Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.